Literature DB >> 22960656

Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection.

Jeremie Martinet1, Tania Dufeu-Duchesne, Juliana Bruder Costa, Sylvie Larrat, Alice Marlu, Vincent Leroy, Joel Plumas, Caroline Aspord.   

Abstract

BACKGROUND & AIMS: Hepatitis B virus (HBV) modulates the immune system to escape clearance. Plasmacytoid dendritic cells (pDCs) initiate antiviral immunity and might determine outcomes of HBV infections. Functional defects in pDCs and natural killer (NK) cells have been reported in patients with chronic HBV infection. However, the mechanisms of these immune dysfunctions and the interactions between pDCs and NK cells have not been determined. We investigated features of pDCs from patients with chronic HBV infection and their interactions with NK cells.
METHODS: We used flow cytometry and cytokine assays to analyze pDCs from patients with chronic HBV infection (118 aviremic and 67 viremic) and compared them with pDCs from uninfected individuals (controls). We performed coculture assays to analyze the ability of pDCs to activate heterologous NK cells.
RESULTS: Circulating and hepatic pDCs from patients with chronic HBV infection had higher levels of activation than pDCs from controls and defective responses to stimulation with Toll-like receptor 9 ligand (TLR9-L), regardless of the patient's viral load. TLR9-L-activated pDCs from viremic patients with HBV did not induce cytolytic activity of NK cells. This altered function of pDCs was associated with reduced expression of OX40L and could be reproduced by incubating control pDCs with plasma from viremic patients with HBV. A high level of interferon-induced protein 10 (IP-10 or CXCL10) and hepatitis B surface and e antigens might induce these defective pDC functions.
CONCLUSIONS: HBV escapes antiviral immunity by altering pDC functions, to disrupt interactions between pDC and NK cells. This could reduce immune control of HBV and lead to chronic infection.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960656     DOI: 10.1053/j.gastro.2012.08.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

Review 3.  NK cells in host responses to viral infections.

Authors:  Viola C Lam; Lewis L Lanier
Journal:  Curr Opin Immunol       Date:  2016-12-13       Impact factor: 7.486

4.  Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.

Authors:  Ludovic Aillot; Marc Bonnin; Malika Ait-Goughoulte; Nathalie Bendriss-Vermare; Sarah Maadadi; Laura Dimier; Miroslava Subic; Caroline Scholtes; Isabel Najera; Fabien Zoulim; Julie Lucifora; David Durantel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 5.  Immune Response in Hepatitis B Virus Infection.

Authors:  Anthony Tan; Sarene Koh; Antonio Bertoletti
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

Review 6.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

Review 7.  Host-virus interactions in hepatitis B and hepatitis C infection.

Authors:  Sachiyo Yoshio; Tatsuya Kanto
Journal:  J Gastroenterol       Date:  2016-02-19       Impact factor: 7.527

Review 8.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

Review 9.  Innate immune targets of hepatitis B virus infection.

Authors:  Zhi-Qiang Zou; Li Wang; Kai Wang; Ji-Guang Yu
Journal:  World J Hepatol       Date:  2016-06-18

Review 10.  Human immune repertoire in hepatitis B virus infection.

Authors:  Qiao Zhan; Jing-Hang Xu; Yan-Yan Yu; Emily Lo Kk; Hani El-Nezami; Zheng Zeng
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.